Y. LEBLANC

The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor

Petpiboon Prasit, Z Wang, Christine Brideau et al. · Bioorganic & Medicinal Chemistry Letters · 1999 · 429 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +9

Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles

Chi‐Chung Chan, S. Boyce, Christine Brideau et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 399 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Design and reactivity of topologically unique, chiral phosphonamides. Remarkable diastereofacial selectivity in asymmetric olefination and alkylation

Stephen Hanessian, Daniel Delorme, Serge Beaudoin et al. · Journal of the American Chemical Society · 1984 · 163 citations

Pharmacy, Chemistry, Medicinal Chemistry +7

From indomethacin to a selective COX-2 inhibitor: Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors

W. Cameron Black, Christopher I. Bayly, Michel Belley et al. · Bioorganic & Medicinal Chemistry Letters · 1996 · 108 citations

Medicine, Medicinal Chemistry, Pharmacology +10

Discovery of MK-0476, a potent and orally active leukotriene D4 receptor antagonist devoid of peroxisomal enxyme induction

Marc Labelle, Michel Belley, Yves Gareau et al. · Bioorganic & Medicinal Chemistry Letters · 1995 · 100 citations

Medicine, Medicinal Chemistry, Pharmacology +7